Open-Label, Phase 2 Clinical Trial of Pre-Surgery and Post-Surgery Immunotherapy With N-803, ETBX-071, and M-CENK in Combination With Surgery for Participants With High-Risk Prostate Cancer Pre-Prostatectomy.
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs ETBX- 071 (Primary) ; Memory cytokine enriched natural killer cell therapy-ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors ImmunityBio
- 15 Jan 2025 New trial record